Barbara Vanderhyden

Barbara Vanderhyden

PhD

Senior Scientist, Cancer Research

Ottawa Hospital Research Institute

Corinne Boyer Chair in Ovarian Cancer Research

University of Ottawa

Distinguished Professor, Cellular and Molecular Medicine

University of Ottawa

Contact

613-737-7700 ext. 70330

501 Smyth Road, Box 926, Ottawa, ON K1H 8L6

Research Groups

Research Group
Vanderhyden Lab
Determining how risk factors contribute to ovarian cancer initiation and progression, single cell analyses and bioinformatics to investigat...

Bio

Barbara Vanderhyden completed her Ph.D. in Reproductive Physiology at the University of Western Ontario in 1988. She then did postdoctoral studies at The Jackson Laboratory in Maine, where she learned to climb mountains, both literally and scientifically. In 1991, she joined the Cancer Research Group at the University of Ottawa, which has evolved into the Cancer Therapeutics Program at the Ottawa Hospital Research Institute, where she is a Senior Scientist. Dr. Vanderhyden is also a Distinguished University Professor at the University of Ottawa and has held the inaugural Corinne Boyer Chair in Ovarian Cancer Research since 2000. She established and ran the university’s transgenic mouse facility for 14 years. In her spare time, she established two science outreach programs, Let’s Talk Science / Parlons sciences, which makes science fun for students in local schools, and Science Travels / La science voyage, which sends teams of grad students to deliver science workshops in remote First Nations and Inuit communities in the far north.


News


Publications

P53 Mutation Induces Epithelial-to-Mesenchymal Transition (EMT) Associated with Stem Cell Properties and Tumorigenesis in Fallopian Tube Cells

2025-10-01 Go to publication

Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses

2023-12-01 Go to publication

Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success

2023-12-01 Go to publication

Conventional DNA-Damaging Cancer Therapies and Emerging cGAS-STING Activation: A Review and Perspectives Regarding Immunotherapeutic Potential

2023-08-01 Go to publication

Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics

2022-11-01 Go to publication

Related Research at The Ottawa Hospital